Swiss National Bank increased its stake in shares of Luminex Co. (NASDAQ:LMNX) by 6.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 67,500 shares of the medical instruments supplier’s stock after purchasing an additional 4,000 shares during the quarter. Swiss National Bank owned 0.15% of Luminex worth $1,330,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently modified their holdings of LMNX. Creative Planning acquired a new stake in Luminex in the fourth quarter valued at $198,000. Crossmark Global Holdings Inc. acquired a new stake in Luminex in the third quarter valued at $254,000. Teacher Retirement System of Texas acquired a new stake in Luminex in the fourth quarter valued at $270,000. Municipal Employees Retirement System of Michigan lifted its holdings in Luminex by 63.6% in the third quarter. Municipal Employees Retirement System of Michigan now owns 15,430 shares of the medical instruments supplier’s stock valued at $314,000 after acquiring an additional 6,000 shares during the period. Finally, Waldron LP acquired a new stake in Luminex in the fourth quarter valued at $330,000. 81.28% of the stock is owned by hedge funds and other institutional investors.
A number of brokerages have recently weighed in on LMNX. BTIG Research initiated coverage on Luminex in a research report on Friday, January 5th. They issued a “buy” rating and a $24.00 price target for the company. BidaskClub upgraded Luminex from a “sell” rating to a “hold” rating in a research report on Friday, February 23rd. Finally, William Blair reiterated a “market perform” rating on shares of Luminex in a research report on Tuesday, February 13th. Four investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $22.33.
LMNX stock traded up $0.09 on Wednesday, reaching $21.70. The company’s stock had a trading volume of 21,465 shares, compared to its average volume of 280,360. The stock has a market cap of $955.74, a PE ratio of 32.25, a price-to-earnings-growth ratio of 2.07 and a beta of 0.16. Luminex Co. has a 52 week low of $17.70 and a 52 week high of $22.42.
Luminex (NASDAQ:LMNX) last posted its quarterly earnings results on Monday, February 12th. The medical instruments supplier reported $0.20 EPS for the quarter, beating the consensus estimate of $0.09 by $0.11. The company had revenue of $78.20 million during the quarter, compared to analysts’ expectations of $77.33 million. Luminex had a return on equity of 8.48% and a net margin of 9.48%. The firm’s revenue was up 8.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.11 EPS. equities analysts predict that Luminex Co. will post 0.64 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 13th. Stockholders of record on Friday, March 23rd will be paid a $0.06 dividend. This represents a $0.24 annualized dividend and a dividend yield of 1.11%. The ex-dividend date is Thursday, March 22nd. Luminex’s dividend payout ratio is currently 35.82%.
TRADEMARK VIOLATION WARNING: “Luminex Co. (NASDAQ:LMNX) Shares Bought by Swiss National Bank” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/03/21/luminex-co-lmnx-shares-bought-by-swiss-national-bank.html.
Luminex Company Profile
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.